Age X Therapeutics, Inc. AGE
We take great care to ensure that the data presented and summarized in this overview for AgeX Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AGE
View allLatest Institutional Activity in AGE
Top Purchases
Top Sells
About AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Insider Transactions at AGE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 28
2025
|
Steven A Ledger Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
95,730
+50.0%
|
-
|
|
Jan 31
2025
|
Juvenescence LTD > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
500,000
+13.27%
|
$5,000,000
$10.0 P/Share
|
|
Dec 17
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
3,866
+5.44%
|
$15,464
$4.59 P/Share
|
|
Nov 27
2024
|
Juvenescence LTD > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
500,000
+15.3%
|
$5,000,000
$10.0 P/Share
|
|
Sep 20
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
1,137
+1.76%
|
$6,822
$6.03 P/Share
|
|
Sep 19
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
11,679
+15.8%
|
$70,074
$6.11 P/Share
|
|
Sep 18
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
2,709
+5.09%
|
$16,254
$6.23 P/Share
|
|
Sep 12
2024
|
Steven Mintz Director |
BUY
Open market or private purchase
|
Indirect |
6,000
+25.59%
|
$36,000
$6.47 P/Share
|
|
Aug 20
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
1,776
+3.6%
|
$14,208
$8.25 P/Share
|
|
Aug 19
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
6,400
+12.26%
|
$44,800
$7.93 P/Share
|
|
Aug 16
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
6,400
+13.97%
|
$44,800
$7.31 P/Share
|
|
Aug 15
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
6,400
+16.24%
|
$38,400
$6.65 P/Share
|
|
Aug 15
2024
|
Steven Mintz Director |
BUY
Open market or private purchase
|
Indirect |
7,593
+33.78%
|
$45,558
$6.59 P/Share
|
|
Aug 15
2024
|
Steven Mintz Director |
BUY
Open market or private purchase
|
Direct |
1,350
+9.92%
|
$8,100
$6.59 P/Share
|
|
Aug 14
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
6,400
+19.39%
|
$44,800
$7.07 P/Share
|
|
Jun 25
2024
|
Steven Mintz Director |
BUY
Open market or private purchase
|
Direct |
2,600
+19.25%
|
$23,400
$9.0 P/Share
|
|
Jun 21
2024
|
Steven Mintz Director |
BUY
Open market or private purchase
|
Direct |
5,000
+37.57%
|
$45,000
$9.5 P/Share
|
|
Jun 06
2024
|
Juvenescence LTD > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
377,865
+14.29%
|
$4,912,245
$13.2 P/Share
|
|
May 30
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
5,205
+20.48%
|
$46,845
$9.5 P/Share
|
|
May 29
2024
|
Gregory Bailey Director |
BUY
Open market or private purchase
|
Direct |
1,173
+7.25%
|
$10,557
$9.5 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 102K shares |
|---|---|
| Grant, award, or other acquisition | 1M shares |
| Exercise of conversion of derivative security | 378K shares |
| Other acquisition or disposition | 95.7K shares |